Nothing said here yet.
to join the conversation.
LOS ANGELES, CA - October 20, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and ...
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.
New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system. Thermo Fisher's clin...
LOS ANGELES, CA - October 6, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement ("SUA") with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-30...
Quantum BioPharma Ltd. (NASDAQ:QNTM) on Tuesday said it is partnering with the clinical research division of Thermo Fisher Scientific Inc. (NYSE:TMO) to launch a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-MS.
The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma's proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previously completed phase 1 clinical ...
In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed. Treatments for progressive forms of MS remain especially elusive, and recent...